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MaOBJECTIVES The purpose of this study was to evaluate the impact of hypertrabeculation and left ventricular (LV)
myocardial noncompaction phenotype by cardiac magnetic resonance (CMR) on outcomes of patients with nonischemic
dilated cardiomyopathy (DCM).
BACKGROUND Myocardial trabeculations and noncompaction are increasingly observed in patients with DCM, but their
prognostic impact remains unknown.
METHODS We prospectively evaluated outcomes of 162 consecutive patients (102 men; age 55  15 years; ejection
fraction [EF] 25  8%) with DCM undergoing CMR. The amount of noncompaction was quantiﬁed as noncompacted/
compacted (NC/C) length in the long-axis view and as the ratio of NC/C mass in the short-axis view and compared against
48 healthy control subjects (age 60  10 years).
RESULTS Fifty-eight DCM patients (36%) had NC/C length $2.3, and 71 (44%) had NC/C mass greater than the 95%
conﬁdence interval (CI) of control subjects. NC/C length and NC/C mass did not correlate with any clinical, echocardio-
graphic, or CMR parameters. Over a 3.4-year median follow-up, 29 patients experienced major adverse cardiovascular
events (MACE) (12 cardiovascular deaths, 8 heart transplantations, 4 LV assist device implantations, and 5 resuscitated
cardiac arrests or appropriate device shocks). Cox univariate analysis identiﬁed smoking, New York Heart Association
functional class, blood pressure, LV and right ventricular end-diastolic and end-systolic volumes, LV EF, right ventricular
EF, and late gadolinium enhancement as predictors of MACE. In multivariate analysis, only LV EF and late gadolinium
enhancement were independent predictors of MACE-free survival (hazard ratio: 0.922, 95% CI: 0.878 to 0.967,
p ¼ 0.001 and HR: 1.096, 95% CI: 1.004 to 1.197, p ¼ 0.04, respectively). Neither NC/C length nor NC/C mass had
signiﬁcant predictive value for MACE-free survival, either unadjusted or after adjustment for baseline variables. Also,
there was no difference in cardioembolic event rate between groups with high and low NC/C length or mass.
CONCLUSIONS Cardiovascular outcomes of adult patients with nonischemic DCM do not appear to be inﬂuenced by
the degree of trabeculation. This argues against a noncompaction phenotype designating a more severe form of DCM.
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AB BR E V I A T I O N S
AND ACRONYM S
BSA = body surface area
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
DCM = dilated cardiomyopathy
ED = end-diastolic
EF = ejection fraction
ES = end-systolic
HR = hazard ratio
ICC = intraclass correlation
coefﬁcient
IQR = interquartile range
LGE = late gadolinium
enhancement
LV = left ventricle/ventricular
LVNC = left ventricular
noncompaction
MACE = major adverse
cardiovascular event
NC/C = noncompacted/
compacted
right ventricle/ventricular
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935that consists of a thin, compacted epicardial layer and
a much thicker, noncompacted endocardial layer.
LVNC was once considered a rare form of heredi-
tary cardiomyopathy (3), with onset in early child-
hood, and was thought to result from the intrauterine
arrest of the normal process of myocardial compac-
tion causing a trabecular meshwork with deep endo-
myocardial spaces. However, this phenotype is now
also increasingly reported in adult patients, probably
because of increased awareness and the improved
imaging capabilities of echocardiography and cardiac
magnetic resonance (CMR).
To date, it remains uncertain whether LVNC is a
distinct type of cardiomyopathy with different path-
ophysiology and outcome from other types of dilated
cardiomyopathies (DCMs). Indeed, different echo-
cardiographic (3,4) and CMR (5,6) diagnostic criteria
have been proposed, and their sensitivity and speci-
ﬁcity to accurately detect LVNC remain controversial
(1,7). Highly variable clinical presentations have been
described, ranging from totally asymptomatic disease
to cardioembolic complications, ventricular arrhyth-
mias, and heart failure. Thus, the prognosis of LVNC
remains unknown (1).SEE PAGE 947Because it allows better visualization of trabecu-
lations than echocardiography, CMR is currently
considered the method of choice to identify LVNC
(5). In the current study, we sought to evaluate
whether the presence of the noncompaction pheno-
type and the amount of LVNC myocardium, assessed
by CMR, inﬂuenced the prognosis of adult patients
with nonischemic DCM. We therefore studied 162
consecutive DCM patients by CMR and evaluated the
utility of noncompaction versus other parameters
in univariate and multivariate survival analysis to
predict overall and cardiovascular mortality and
morbidity.
METHODS
STUDY POPULATION. The study was approved by the
institutional review board. From a prospective regis-
try of all patients referred to our institution for per-
formance of CMR for myocardial characterization
with late gadolinium enhancement (LGE) between
2003 and 2013, we evaluated the follow-up of patients
with a diagnosis of DCM based on World Health
Organization/European Society of Cardiology recom-
mendations, who had dilated LV volumes and ejec-
tion fraction (EF) <40% as measured by CMR.
Exclusion criteria were ischemic etiology by coronary
angiography or coronary computed tomographyaccording to the criteria proposed by Felker
et al. (8), and additionally, presence of sub-
endocardial or transmural LGE suggestive of
previous myocardial infarction (9). We also
excluded patients with a poor life expec-
tancy, such as patients with metastatic can-
cer, patients in palliative care, and patients
hospitalized for terminal heart failure who
were not considered candidates for heart
transplantation. Patients with secondary
cardiomyopathies (10) attributable to car-
diotoxic chemotherapy, HIV, neuromuscular
diseases, or coexisting severe primary valve
disease and cardiomyopathies due to revers-
ible causes such as endocrine disorders,
hypertensive cardiomyopathy, and tachy-
cardiomyopathy were also excluded. A total
of 162 patients satisﬁed these criteria and
constituted the ﬁnal study population
(Figure 1).
CLINICAL AND ECHOCARDIOGRAPHIC DATA.
Clinical data (including data on cardiovascu-
lar risk factors, comorbidities, and New York
Heart Association functional class), electro-
cardiogram, laboratory tests, peak VO2 exercise test,
coronary angiography, and treatment were collected
by review of medical records. Two-dimensional
echocardiography data acquired within a median of
9 days (interquartile range [IQR]: 4 to 28 days) from
the CMR examination and stored on a database server
(Xcelera, Philips Healthcare, Best, the Netherlands)
were analyzed by a single observer (M.-S.A.). Five
echocardiography studies were unavailable for re-
view. Diastolic function assessment (E/A mitral waves
and E/e0 ratio) was available only for 127 patients and
was missing in 30 patients because of atrial ﬁbrilla-
tion or ﬂutter (n ¼ 10), sinus tachycardia (n ¼ 19), or
ventricular bigeminy (n ¼ 1). Pulmonary artery sys-
tolic pressure was computed by adding the tricuspid
regurgitation pressure gradient to the right atrial
pressure estimated from the inferior vena cava di-
mensions and inspiratory collapse.
CMR STUDIES. CMR studies were performed on 1.5-T
or 3-T units (Intera-CV and Achieva, Philips Medical
Systems, Best, the Netherlands) as reported previ-
ously (11). Brieﬂy, 10 to 12 consecutive short-axis
images covering the entire LV and 2-, 3-, and
4-chamber long-axis images were acquired with a
cine steady-state free precession sequence to allow
assessment of myocardial function and mass and
quantiﬁcation of noncompaction. Ten to 15 min after
injection of 0.2 mmol/kg gadolinium contrast agent,
LGE images were acquired by a 2- or 3-dimensional
RV =
FIGURE 1 Flow Chart of Included and Excluded Patients
The ﬂow chart presents the selection criteria of the study population from a cardiac magnetic resonance (CMR) registry at our institution.
CAD ¼ coronary artery disease; DCM ¼ dilated cardiomyopathy; EF ¼ ejection fraction; HIV ¼ human immunodeﬁciency virus; LGE ¼
late gadolinium enhancement.
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936inversion recovery sequence in identical short- and
long-axis slices.
CMR studies were analyzed with the freely
available software Segment version 1.9 (Medviso,
Lund, Sweden) (12) by the same observer. Right
ventricular (RV) and LV volumes, mass, and EF were
computed from the short-axis cine images by semi-
automatic tracing of the endocardial and epicardial
contours in the end-diastolic (ED) and end-systolic
phases. Values were indexed to the body surface
area (BSA).
LV trabeculations, identiﬁed as any endocardial
wall contour irregularities present in the ED phase,
distinct from papillary muscles and chordae, were
measured by 2 previously described methods. In
method 1 (Figure 2), according to Petersen et al. (5), on
long-axis images, the lengths of compacted andnoncompacted layers of the most trabeculated
segment (excluding the true apex, segment 17) were
measured in ED and reported as noncompacted to
compacted (NC/C) length ratio. In method 2 (Figure 3),
according to Jacquier et al. (6), on short-axis images
in ED, LVNC mass was measured as the difference
between the global LV mass (LV trabeculations
included in the endocardial tracing) and compacted
mass (LV trabeculations excluded from the endocar-
dial tracing) and reported as NC/C mass ratio. The
papillary muscles were each time excluded from the
LV mass calculation.
Presence, localization, and extent of LGE were
evaluated visually and quantiﬁed with a semi-
automated algorithm (Segment software) (12) as
reported previously (11). LGE patterns were charac-
terized as mid-wall, epicardial, or patchy.
FIGURE 2 Illustration of the Approach Used to Quantify NC/C Length
The maximal noncompacted (NC) myocardium length in any of the 4-, 3-, and 2-chamber
views (red line) and the corresponding compacted (C) myocardium length (green line)
were measured in end diastole.
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937LA volume indexed to BSA was computed by the
biplane area-length method on 4- and 2-chamber
end-systolic cine images with Osirix software
version 5.8 (Pixmeo, Geneva, Switzerland). Mitral
regurgitation volume was computed as the difference
between LV stroke volume by the Simpson method
and phase-contrast aortic forward ﬂow. Lastly, the
presence of excessive RV trabeculations was evalu-
ated visually in the short-axis stacks.
Normal values of CMR parameters and of NC/C
length and mass were deﬁned in a population of 48
healthy volunteers (n ¼ 22 males, mean age 60  10
years, mean BSA 1.8  0.2 m2) without a history of
cardiovascular disease and with unremarkable phys-
ical examination and electrocardiogram and normal
computed tomography coronary angiography.
FOLLOW-UP AND ENDPOINT. Follow-up was per-
formed by telephone contact of patients/family and
physicians between January 2014 and August 2014
and by review of medical records for a total of 612
person-years. Follow-up was complete for all but 1
patient. The cause of death was categorized as cardiac
or noncardiac. Cardiac death was deﬁned as death
attributable to congestive heart failure (i.e., death
preceded by acute exacerbation or worsening of heart
failure) or sudden death (i.e., unexpected, unwit-
nessed, or witnessed death in the absence of other
apparent causes). Appropriate device intervention
was deﬁned as device shock or antitachycardia pacing
delivered in response to a documented ventricular
tachyarrhythmia.
The primary endpoint of our study was a composite
endpoint of major adverse cardiovascular events
(MACE) comprising cardiovascular death, heart trans-
plantation, LV assist device implantation, resuscitated
cardiac arrest, and appropriate device shocks. Sec-
ondary endpoints were all-cause mortality, cardio-
vascular mortality, stroke and embolic events.
STATISTICAL ANALYSIS. Statistical analysis was
performed with SPSS version 15.0 (SPSS Inc., Chicago,
Illinois). Continuous variables are presented as
mean  SD or as median (IQR) and categorical vari-
ables as counts and percentages. Comparisons be-
tween groups were performed with a 2-sided Student
t test, Wilcoxon-Mann-Whitney U test, and chi-square
or Fisher exact test for categorical variables, as
appropriate. Correlation was performed with the
Pearson test. Values of p < 0.05 were considered
statistically signiﬁcant. Under the assumption that
one-third of patients have high NC/C, our study had
80% power to detect a 153% higher event rate (i.e.,
62% vs. 85% MACE-free survival) with a ¼ 0.05.
On the basis of the 2 methods described above,
the study population was divided into groupsaccording to the degree of noncompaction, expressed
as either the NC/C length or the NC/C mass. The
cutoff values used to deﬁne the groups were NC/C
length $2.3 (as proposed by Petersen) and NC/C
mass $95% conﬁdence interval (CI) (i.e., $31%) of
control subjects.
The index date was the date of the CMR examina-
tion. The duration of follow-up was computed using
the index date to the date of the ﬁrst MACE or last
clinical follow-up. Kaplan-Meier survival and Cox
proportional hazards analyses were used to assess the
relationship between the degree of NC by the 2
methods presented and MACE. Survival curves were
compared with the log-rank (Mantel-Cox) test.
Hazard ratios (HRs) are expressed as mean and 95%
CIs. All signiﬁcant univariate predictors of MACE
were proposed for inclusion in multivariate forward
and backward stepwise Cox models. The model with
the lowest Akaike and Bayesian information criteria
was retained. The predictive values of NC/C length
and NC/C mass were evaluated both unadjusted and
after adjustment for baseline predictors of MACE.
Intraobserver and interobserver agreement for non-
compaction measurement were tested in 15 randomly
selected cases according to the Bland-Altman method
and expressed as bias  SD (95% CI) and intraclass
correlation coefﬁcients (ICCs).
RESULTS
Clinical, echocardiographic, and CMR results of the
patient population are presented in Tables 1 and 2,
respectively.
FIGURE 3 Illustration of the Approach Used to NC/C Mass Ratio
(A) Compacted mass was quantiﬁed by excluding left ventricular (LV) trabeculations from the endocardial tracing. (B) Global mass was
quantiﬁed by including LV trabeculations in the endocardial tracing. Papillary muscles were always excluded. Noncompacted (NC) myocardial
mass was computed as the difference between global and compacted mass. NC/C ¼ noncompacted/compacted.
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938DETECTION OF NONCOMPACTION BY CMR. Intra-
observer and interobserver variability for measuring
NC/C length were 0.06  0.56 (95% CI: 0.54 to 1.67)
and 0.11  1.06 (95% CI: 1.00 to 3.13), with ICCs of
0.91 and 0.70, respectively. Intraobserver and inter-
observer variability for measurement of non-
compacted mass were 0.98  4.4% (95% CI: 4.27%
to 13.2%) and 2.815  3.37% (95% CI: 3.24% to
9.99%), with ICCs of 0.97 and 0.991, respectively.
Median (IQR) NC/C length and average NC/C mass
in healthy volunteers were 1.5 (IQR: 1.1 to 2) and17  7%, respectively. Eight control subjects (17%) had
NC/C length $2.3. Patients with DCM had signiﬁ-
cantly greater median (IQR) NC/C length (1.8 [IQR: 1.2
to 2.6]; p < 0.01) and average NC/C mass (31  15%;
p < 0.001) than volunteers. Noncompacted segments
were mainly located at the mid and apical segments
and the nonseptal regions and followed a similar
distribution in patients as in control subjects.
Using the 2 previously described criteria for diag-
nosis of noncompaction (i.e., NC/C length $2.3
or $95% CI [$31%] of NC/C mass of volunteers), we
TABLE 1 Clinical Characteristics of Patients
All Patients
(n ¼ 162)
NC/C Length <2.3
(n ¼ 103)
NC/C Length $2.3
(n ¼ 59)
NC/C Mass <31%
(n ¼ 90)
NC/C Mass $31%
(n ¼ 72)
Age, yrs 55  15 56  16 52  13 56  15 53  15
Male 102 (63) 68 (66) 34 (58) 60 (67) 42 (58)
BSA, m2 1.9  0.2 1.9  0.2 1.9  0.2 1.9  0.2 1.9  0.2
African 16 (10) 4 (4) 4 (8) 3 (3) 5 (7)
SBP, mm Hg 120  17 122  19 117  20 125  19* 114  18
DBP, mm Hg 74  14 75  14 71  13 76  15 72  12
Heart rate, beats/min 80  16 79  16 81  15 79  16 81  15
Smoker 74 (46) 49 (48) 25 (43) 44 (49) 30 (42)
Arterial hypertension 59 (37) 43 (42) 16 (28) 40 (45)* 19 (27)
Dyslipidemia 60 (38) 37 (36) 23 (40) 34 (38) 26 (37)
Diabetes mellitus 22 (14) 16 (16) 6 (10) 15 (17) 7 (10)
Stroke 15 (9) 8 (7) 7 (12) 9 (10) 6 (8)
COPD 12 (7) 7 (7) 5 (9) 6 (7) 6 (8)
NYHA functional class I-II/III-IV, % 51/49 46/55 62/38 52/48 51/49
MDRD, ml/min/1.73 m2 74  25 75  26 74  23 72  23 77  26
Hemoglobin, mg/dl 13.8  1.6 13.7  1.6 13.9  1.6 13.7  1.6 13.9  1.6
AF 16 (10) 14 (14)† 2 (3) 12 (14) 4 (6)
LBBB 59 (37) 38 (38) 21 (36) 34 (39) 25 (35)
LVEDD, mm 68  9 67  9 69  9 67  10 69  9
LV FS, % 14  6 14  6 14  5 14  6 13  5
E/A 1.7  0.8 1.4  0.8 1.5  0.8 1.4  0.7 1.6  0.9
E/e0 15.8  6.7 15.8  6.4 15.7  7.1 15.7  6.4 16  7.4
PASP, mm Hg 34.5  14.6 34.5  14.6 34.5  14.7 34.2  14.6 35.1  14.7
Increased LV ﬁlling pressure 51 (48) 31 (51) 20 (44) 34 (50) 17 (44)
MR degree I/II/III, % 80/16/4 77/21/2 84/9/7 77/20/3 82/12/6
Peak VO2, ml/kg/min 16.7  6.2 17.5  7.3 16.0  4.9 16.6  5.8 16.8  6.6
Peak VO2, ml/kg/min, % of predicted 53.9  18.4 55.0  19.7 52.7  17.3 54.3  18.7 53.4  18.3
VE/VCO2 slope 34.6  10.6 35.2  12.6 34.0  8.3 34.9  12.6 34.3  8.6
Treatment
ACEI or ARB 158 (98) 99 (97) 59 (100) 86 (97) 72 (100)
Beta-blocker 145 (90) 94 (92) 51 (86) 80 (90) 65 (90)
Aldosterone antagonist 110 (68) 69 (68) 41 (70) 58 (65) 52 (72)
Loop diuretic 101 (63) 68 (67) 33 (56) 53 (60) 48 (67)
Aspirin 73 (45) 46 (45) 27 (46) 41 (46) 32 (45)
Anticoagulant 35 (22) 22 (22) 13 (22) 20 (23) 15 (21)
Statin 45 (28) 26 (26) 19 (32) 25 (28) 20 (28)
CRT-P 23 (14) 13 (13) 10 (17) 10 (11) 13 (18)
CRT-D 10 (6) 7 (7) 3 (5) 5 (6) 5 (7)
ICD 10 (6) 5 (5) 5 (9) 4 (5) 6 (9)
Values are mean  SD or n (%). *p < 0.05 versus NC/C-mass $31%. †p < 0.05 versus NC/C-length $2.3.
ACEI ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; BNP ¼ brain natriuretic peptide; BSA ¼ body surface area; COPD ¼ chronic obstructive
pulmonary disease; CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator; CRT-P ¼ cardiac resynchronization therapy with pacemaker; DBP ¼ diastolic blood pressure; ICD ¼ implantable cardioverter-
deﬁbrillator; LBBB ¼ left bundle branch block; LV ¼ left ventricular; LVEDD ¼ left ventricular end-diastolic diameter; LV FS ¼ left ventricular fractional shortening; MDRD ¼ Modiﬁcation of Diet in Renal
Disease estimate of glomerular ﬁltration rate; MR ¼ mitral regurgitation; NC/C ¼ ratio of noncompacted to compacted myocardium; NYHA ¼ New York Heart Association; PASP ¼ pulmonary artery systolic
pressure; SBP ¼ systolic blood pressure.
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939classiﬁed DCM patients into groups with a high or
low degree of noncompaction. Respectively, 58 DCM
patients (36%) had maximum NC/C length $2.3,
whereas 71 (44%) had NC/C mass $31%. Forty-four
patients (27%) presented with both criteria.
Although the correlation between NC/C length and
NC/C mass in patients was satisfactory (r ¼ 0.62), the
agreement of the 2 methods to classify patients intogroups with high and low degrees of noncompaction
was poor (k < 0.2, p ¼ 0.0001).
As shown in Table 1, except for higher systolic
blood pressure and presence of hypertension in
patients with NC/C mass <31% and a higher preva-
lence of atrial ﬁbrillation in patient with NC/C
length <2.3, there were no other statistical differ-
ences between the groups of patients with high and
TABLE 2 CMR Parameters
All Patients
(n ¼ 162)
NC/C Length <2.3
(n ¼ 103)
NC/C Length $2.3
(n ¼ 59)
NC/C Mass <31%
(n ¼ 90)
NC/C Mass $31%
(n ¼ 72)
NC/C length 1.8 (1.2–2.6) 1.4 (1–1.8) 3 (2.6–3.5) — —
NC/C mass 31  15 — — 21  6 44  12
Average LV wall thickness, mm 8  1.4 8.1  1.4 7.7  1.5 8.5  1.4* 7.4  1.2
Presence of excessive RV trabeculations 12 (7) 3 (3)† 9 (15) 3 (3)* 9 (13)
Mural thrombi 4 (2) 2 (2) 2 (3) 2 (2) 2 (3)
LVMi, g/m2 93  25 93.2  22 92.7  29.5 97.7  23.3* 87.2  25.8
LVEDVi, ml/m2 161.6  52 157.2  47.3 169.4  58.5 156  48.3 168.7  55.4
LVESVi, ml/m2 124.5  50.7 120.7  47.1 131.3  56.2 118.3  47.2 132.3  54.1
LVEF, % 24.6  8.4 24.8  8.6 24.1  8.3 25.7  8.3 23.2  8.5
RVEDVi, ml/m2 88.3  35.2 86.8  32.7 91  39.5 84.7  30.8 92.7  40
RVESVi, ml/m2 55.5  34.5 54.6  32 57.2  38.7 51.5  29.7 60.5  39.3
RVEF, % 41  14.2 40.2  13.3 42.1  15.7 42  13.1 40  15.4
LAVi, ml/m2 62.6  28.5 61.5  24.5 64.6  34.4 60.8  23.6 65  33.7
MR volume, ml 10 (4–20) 8.3 (3.8–20.5) 11 (5–21) 8.3 (3.3–20.2) 10.4 (4.7–22.3)
LGE 63 (39) 41 (40) 22 (37) 31 (35) 32 (44)
LGE, % LV 0.5 (0.2–1.6) 0.5 (0.2–1.7) 0.5 (0.2–1.6) 0.4 (0.2–1.2) 0.6 (0.3–2)
Midseptal stripe 47 (29) 31 (30) 16 (27) 22 (25) 25 (35)
Values are median (interquartile range), mean  SD, or n (%). *p < 0.05 vs. NC/C mass $31%. †p < 0.001 vs. NC/C length $2.3.
CMR ¼ cardiac magnetic resonance; LAVi ¼ left atrial volume (indexed); LGE ¼ late gadolinium enhancement; LVMi ¼ left ventricular mass (indexed); LVEDVi¼ left ventricular end-diastolic
volume (indexed); LVESVi ¼ left ventricular end-systolic volume (indexed); LVEF ¼ left ventricular ejection fraction; RV ¼ right ventricular; RVEDVi ¼ right ventricular end-diastolic volume
(indexed); RVESVi ¼ right ventricular end-systolic volume (indexed); RVEF ¼ right ventricular ejection fraction; other abbreviations as in Table 1.
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940low NC/C length and NC/C mass in terms of clinical,
electrocardiographic, or echocardiographic charac-
teristics, severity of heart failure, or treatment.
Also, except for average LV wall thickness and LV
mass index (which were signiﬁcantly higher in the
NC/C mass <31% group than in the NC/C mass
$31% group [p < 0.05]), there were no statistical
signiﬁcant differences between groups for any CMR
parameters. RV trabeculations were statistically more
prevalent in the groups with a higher degree of LV
noncompaction (Table 2).
Neither NC/C length nor NC/C mass ratio of pa-
tients showed a signiﬁcant correlation with any clin-
ical, magnetic resonance, or echocardiographic
parameter of disease severity. Intramural thrombi
were observed in similar proportions in patients with
high and low NC/C length or NC/C mass ratio.
SURVIVAL. Over a median (IQR) follow-up of 3.4
years (1.5 to 6.3 years), 29 patients experienced
MACE: 12 cardiovascular deaths (7 sudden, 5 wors-
ening heart failure), 8 heart transplantations, 4 LV
assist device implantations, and 5 arrhythmic events
(1 resuscitated cardiac arrest, 3 appropriate device
shocks, and 1 antitachycardia pacing). In addition, 8
noncardiovascular deaths were recorded. Four pa-
tients had stroke, 1 in the NC/C mass $31% group and
2 in the NC/C length $2.3 group. Odds ratio for stroke
in groups with high NC/C mass and length were 0.41
(95% CI: 0.04 to 4.0; p ¼ 0.63) and 1.77 (95% CI: 0.24to 12.9; p ¼ 0.62), respectively. There were no other
thromboembolic events recorded.
MACE occurred in 18 (17%) and 11 (19%) patients
from the NC/C length <2.3 and NC/C length $2.3
groups and in 19 (21%) and 10 (14%) patients from the
NC/C mass <31% and NC/C mass $31% groups,
respectively. The MACE-free survival Kaplan-Meier
curves did not show a statistically signiﬁcant differ-
ence in outcome for the NC/C length and NC/C mass
groups (Figure 4). Likewise, for the secondary end-
points (all-cause mortality and cardiovascular mor-
tality), there were no differences between patients
with high and low amounts of noncompaction,
assessed as either NC/C length or NC/C mass. To
further study the inﬂuence of noncompaction on
prognosis, we also classiﬁed patients into tertiles
of NC/C length and NC/C mass. As shown in Figures 5
to 7, the groups with the highest degree of non-
compaction did not experience worse outcomes than
those in the lowest tertile of noncompaction.
Cox univariate predictors of MACE are listed in
Table 3. NC/C length and NC/C mass, both as contin-
uous and as binary parameters, were not associated
with a worse prognosis, either unadjusted or after
adjustment for baseline variables (HR: 1.08; 95% CI:
0.74 to 1.6, p¼0.88 for NC/C length and HR: 1.001, 95%
CI: 0.98 to 1.03, p ¼ 0.93 for NC/C mass). By multivar-
iate analysis, only LV EF and the amount of LGE were
independent predictors of MACE-free survival.
FIGURE 4 MACE-Free Survival Curves According to Degree of Trabeculation
Kaplan-Meier estimates of survival free of major adverse cardiovascular events (MACE) in the groups of patients with high and low degrees of noncompaction, expressed
as ratio of noncompacted to compacted myocardium length (NC/C length) (A) and mass (NC/C mass) (B). NS ¼ nonsigniﬁcant.
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941DISCUSSION
The ﬁndings of the present study can be summarized
as follows. 1) Adult patients with DCM had an
increased degree of myocardial trabeculations when
assessed by CMR and frequently satisﬁed previously
reported criteria for diagnosis of noncompacted car-
diomyopathy. 2) The presence and amount of LVNC
myocardium measured by CMR did not correlate with
disease severity and did not predict subsequent car-
diovascular mortality and morbidity. 3) The prognosis
of our patients was inﬂuenced only by the magnitude
of LV and RV remodeling and systolic dysfunction
and by the presence and amount of LGE, but not by
the noncompaction phenotype.
DIAGNOSIS OF NONCOMPACTION CARDIOMYOPATHY.
At present, the diagnosis of LVNC cardiomyopathy is
purely morphological and based on the detection of
increased amount of trabeculated myocardium. So
far, no consensus has been reached on a generally
accepted and binding deﬁnition of LVNC. Indeed,
different echocardiographic (3,4) and CMR (5,6)
criteria exist for the deﬁnition of LVNC, with several
proposed diagnostic cutoff values, all of which
were established in small populations. For CMR, 2
different criteria were proposed: Petersen et al. (5)
suggested measuring the length of noncompactedand compacted segments on long-axis steady-state
free precession cine images in end diastole, at a site
with the most prominent trabeculations, and deﬁned
a ratio of NC/C length $2.3 as abnormal. By contrast,
Jacquier et al. (6) proposed measurement of the LV
trabeculated mass as the difference between the
global and compacted LV mass on consecutive short-
axis images in end diastole. The latter authors pro-
posed a cutoff of >20% as being able to distinguish
LVNC from patients with a normal amount of LV
trabeculation (as seen in DCM, hypertrophic cardio-
myopathy, and healthy control subjects). In our
study, the 95% CIs of the noncompacted mass of
healthy volunteers were higher than in the data pre-
sented by Jacquier et al. (6), and we consequently
used a higher cutoff value of noncompacted mass to
deﬁne abnormal trabeculation. Although in our
study, both methods had good intraobserver and
interobserver agreement and acceptable correlation
for measuring noncompacted myocardium, the clas-
siﬁcation into groups of patients with abnormal and
normal noncompaction by the 2 approaches disagreed
strongly.
When we applied the Petersen criteria (5) to our
healthy volunteers, an NC/C length $2.3 was present
in as many as 17% of them. This is consistent with a
report of the Multi-Ethnic Study of Atherosclerosis
FIGURE 5 MACE-Free Survival Curves According to Increasing Degree of Trabeculation
Kaplan-Meier estimates of survival free of major adverse cardiovascular events (MACE) according to tertiles of noncompacted to compacted myocardium (NC/C) length
(A) and NC/C mass (B). NS ¼ nonsigniﬁcant.
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942(MESA), in which 44% of 306 healthy patients met a
criterion of increased noncompaction (13). An addi-
tional problem with the deﬁnition of noncompaction
is the increased prevalence of both LV trabecula-
tions and criteria for LVNC in African patients with
heart failure compared with Caucasians. Therefore,
the current diagnostic criteria may lack accuracy
and speciﬁcity and lead to an overdiagnosis of
LVNC (7).
Moreover, it is still not clear whether LVNC is
truly a distinct cardiomyopathy or an epiphenom-
enon of other cardiomyopathies. Indeed, the Amer-
ican Heart Association considers noncompaction
cardiomyopathy as a new type of genetic cardiomy-
opathy (10). By contrast, according to a 2008
European Society of Cardiology position statement
paper (14), LVNC remains an unclassiﬁed cardiomy-
opathy. Indeed, patients with LVNC show genetic
heterogeneity (1) and different phenotypic expres-
sion. Also, the noncompaction phenotype has been
observed in several cardiomyopathies of different
origins, including DCM (15), neuromuscular disorders(16), and congenital heart disease (17), as well as in
athletes (18) and healthy populations (13), and may
even appear transiently during pregnancy (19).
Although the deﬁnition of LVNC would clearly beneﬁt
from a genotype-phenotype correlation, mutations
described in LVNC affect genes of proteins that link
the extracellular matrix of the myocardial cell to the
cytoskeleton, such as ZASP, alpha-dystrobrevin, and
tafazzin (20,21) which overlaps with other forms
of DCM.
HYPERTRABECULATION AND LV NONCOMPACTION
IN DCM. Our study shows that an NC/C length $2.3
and an increased NC/C mass are common ﬁndings in
DCM. The 2 suggested diagnostic criteria for LVNC
were present in 36% and 44% of patients with DCM,
respectively. This is in agreement with other recent
works (7) that also reported that a high percentage of
patients with heart failure have noncompaction.
This calls into question whether noncompaction in
DCM truly indicates a different type of disease.
Indeed, LVNC in DCM could simply arise from
greater visibility or more pronounced separation of
FIGURE 6 All-Cause Mortality–Free Survival Curves
Kaplan-Meier estimates of survival free of all-cause mortality according to tertiles of noncompacted to compacted myocardium (NC/C) length (A) and NC/C mass (B).
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943trabeculations when the LV cavity dilates, or it could
be the result of the remodeling process or the loading
conditions of the LV. This is compatible with reports
of reversal of LVNC phenotype after cardiac
resynchronization therapy (22) and in the post-
partum period of pregnant women (19).
In our study, the amount of noncompaction did not
correlate with the extent of LV ventricular dysfunc-
tion and was related to neither clinical nor echocar-
diographic markers of disease severity. In contrast
to some other reports (23), we did not ﬁnd a correla-
tion between the noncompaction phenotype and
the presence of LGE. This argues against noncom-
paction phenotype indicating a different or more
severe form of DCM, as some previous small studies
have suggested (23).
PROGNOSTIC IMPLICATIONS OF NONCOMPACTION
PHENOTYPE IN DCM. To date, there have been con-
tradictory reports regarding the prognosis of patients
with LVNC, mainly because of the heterogeneity of
the population studied and the lack of consensus
in LVNC deﬁnition. Earlier studies (24), in particular
in pediatric populations (3), in whom the diseasemay be associated with facial dysmorphism and
Wolff-Parkinson-White syndrome, reported an in-
creased mortality caused by heart failure, arrhythmia,
and thromboembolic events. More recent reports in
adult patients with noncompaction and LV dysfunc-
tion have been conﬂicting (25–28).
In our study, the cardiovascular mortality and
morbidity of adult patients with nonischemic DCM
were not inﬂuenced by the presence of higher
degrees of noncompacted myocardium. This is in
agreement with a recent report that demonstrated
that hypertrabeculation in asymptomatic subjects in
MESA was not associated with deterioration in LV
volumes or function or worse outcome over a 10-year
follow-up (29). Overall, we observed low mortality,
arrhythmic events, and strokes, even in the group of
patients with the highest degree of noncompaction.
Our ﬁndings may somewhat be at odds with recent
studies that suggested that greater degrees of non-
compaction as assessed by magnetic resonance
imaging predict a greater number of events (27,30).
However, in our study, we included only patients with
DCM and low EF, unlike previous reports that also
FIGURE 7 CV Mortality–Free Survival Curves
Kaplan-Meier estimates of survival free of cardiovascular (CV) mortality according to tertiles of noncompacted to compacted myocardium (NC/C) length (A) and
NC/C mass (B).
TABLE 3 Cox Univariate and Multivariate Predictors for MACE
Univariate Analysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI) p Value
Smoker* 2.242 (1.043–4.827) 0.039 — —
SBP, mm Hg* 0.977 (0.956–0.999) 0.038 — —
DBP, mm Hg* 0.967 (0.938–0.996) 0.028 — —
NYHA functional class* 1.391 (0.975–1.984) 0.069 — —
LVEDVi, per 10 ml/m2* 1.097 (1.046–1.151) 0.0001 — —
LVESVi, per 10 ml/m2 1.108 (1.055–1.164) 0.0001 — —
LVEF, %* 0.915 (0.871–0.962) 0.0001 0.922 (0.878–0.967) 0.001
RVEDVi, per 10 ml/m2* 1.118 (1.023–1.222) 0.014 — —
RVESVi, per 10 ml/m2 1.148 (1.050–1.255) 0.002 — —
RVEF, %* 0.960 (0.935–0.987) 0.004 — —
LAVi, per 10ml/m2* 1.097 (0.991–1.215) 0.075 — —
Presence of LGE 1.887 (0.907–3.924) 0.089 — —
LGE, % LV* 1.117 (1.024–1.218) 0.013 1.096 (1.004–1.197) 0.040
NC/C length 1.026 (0.725–1.454) 0.883 — —
NC/C mass, % 1.009 (0.984–1.034) 0.482 — —
*Variables included in the Cox multivariate model.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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944included patients with preserved EF and compared
the outcome of patients with or without non-
compaction to patients with DCM. Moreover, it has
been shown that the prognosis of patients with non-
compaction is mainly affected by the presence of heart
failure symptoms, LV dilatation, and systolic dys-
function (31). Indeed, in agreement with other works
(9,32), we observed that parameters reﬂecting LV and
RV remodeling and in particular LV dysfunction and
the presence and extent of LGE were statistically sig-
niﬁcant predictors of outcome in our DCM population.
CLINICAL IMPLICATIONS. Our study demonstrated
that increased degrees of trabeculation did not pre-
dict worst clinical outcomes, and hence, the non-
compaction phenotype is not an important risk factor
in patients with DCM. This argues against screening
for LVNC and systematically measuring the NC/C ra-
tio in DCM by CMR and against adopting a more
aggressive therapeutic attitude in DCM patients in
whom an LVNC phenotype is identiﬁed by CMR. By
contrast, the fact that parameters of biventricular
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Hypertrabecu-
lation and noncompaction phenotype are frequently observed by
cardiac magnetic resonance imaging in patients with dilated
cardiomyopathy. The presence of this phenotype was not asso-
ciated with worse clinical outcome.
TRANSLATIONAL OUTLOOK: Because this is a relatively
small study, larger studies are needed to conﬁrm the impact of
hypertrabeculation and noncompaction phenotype on outcome
of patients with dilated cardiomyopathy. Our data suggest,
however, that treatment of patients with dilated cardiomyopathy
should not be inﬂuenced by the presence of an increased amount
of trabeculation.
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945remodeling and function were the most important
predictors of outcome in our population supports the
use of these classic parameters for risk assessment
and selection of medical and device treatment in DCM
patients.
STUDY LIMITATIONS. Although our study is the
largest to date, the relatively low number of events
limited statistical power, enabled only the detection
of relatively large effects, reduced our ability to
control for the sources of possible confounding
variables, and exposed a potential risk of overﬁtting
in multivariate models. Larger multicentric studies
will be required to better understand the clinical
implications of the noncompaction phenotype in
DCM. The study included consecutive patients
referred to our tertiary center, with a potential
referral bias for CMR. Also, we excluded patients
with EF >40% and those with neuromuscular dis-
eases and other secondary cardiomyopathies (10),
which may also display the LVNC phenotype.
Therefore, the study conclusions cannot neces-
sarily be extrapolated to these populations. Finally,
our study conclusions only apply to trabeculation
detected by CMR.
CONCLUSIONS
The cardiovascular mortality and morbidity of adult
patients with nonischemic DCM are inﬂuenced by
the magnitude of biventricular remodeling and
dysfunction and by the presence and amount of LGEdetected by CMR. By contrast, the prognosis did not
appear to be inﬂuenced by the degree of LV myocar-
dial trabeculation. This argues against the non-
compaction phenotype being a more severe form
of DCM.
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